Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Biotech
Novo left praying to Artemis and Hermes as CKD trial flops
The trial has missed its primary goal, denting the prospects of a molecule analysts tipped to yield blockbuster sales and diversify Novo's portfolio.
Nick Paul Taylor
Jul 31, 2026 8:57am
In deal fraud dispute with Novo, KBP looks to revive heart drug
Apr 1, 2026 2:30am
Maze stock plummets after potential 'best-in-class' ph. 2 data
Mar 25, 2026 10:57am
R1 debuts with $77.5M to advance kidney disease treatment
Mar 17, 2026 7:00am
United Therapeutics' temporary liver shows promise in trial
Jan 27, 2026 9:00am
Boehringer spells out a $448M future for Rectify's ABC program
Dec 22, 2025 9:45am
